Please login to the form below

cladribine

This page shows the latest cladribine news and features for those working in and with pharma, biotech and healthcare.

alemtuzumab, ocrelizumab, ofatumumab and cladribine.

NICE recommends Novartis’ Rydapt for advanced SM treatment

NICE said that clinical trials showed an increase in overall survival of 23% for people with advanced SM when treated with Rydapt compared to other treatments, which include interferon alpha, cladribine
Dupixent gains can’t keep Sanofi on a growth track

despite greater competition from drugs like Roche’s Ocrevus (ocrelizumab), Novartis’ Mayzent (siponimod) and Merck KGaA’s Mavenclad (cladribine).
MS and cholesterol drugs picked for new UK rapid uptake push

Merck’s Mavenclad (cladribine) for treating highly active relapsing-remitting multiple sclerosis in adults - A drug for multiple sclerosis with a novel mode of action, high efficacy and a low treatment
Sanofi licences Principia MS drug in $805m deal

The three established players in the oral MS therapy category are also about to see additional competition from new entrant Merck KGaA, which bagged EU approval for Mavenclad (cladribine) in August.
Merck mulls sale of consumer health division

The news comes a few days after Merck picked up an important new approval for its pharma division in Europe, with the EMA clearing Mavenclad (cladribine) for the treatment of

More from news
Approximately 2 fully matching, plus 28 partially matching documents found.

XenoPort appoints chief medical officer

Prior to joining Biogen Idec Dr Kim was with Merck Serono, serving as medical director for the phase III programme of cladribine, which failed to impress in MS.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Early Access Program - Regulatory Affairs (EAP-RA): Highly competitive salary

Associate Director - Global Healthcare Consulting: Highly competitive salary

Add my company

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Virtual Patient Engagement Program: A Customer Story: Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?: Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all: The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...

Email:
Password: